U.S. markets open in 1 hour 54 minutes
  • S&P Futures

    4,609.00
    -45.75 (-0.98%)
     
  • Dow Futures

    35,539.00
    -257.00 (-0.72%)
     
  • Nasdaq Futures

    15,349.75
    -246.00 (-1.58%)
     
  • Russell 2000 Futures

    2,136.90
    -20.80 (-0.96%)
     
  • Crude Oil

    84.94
    +1.12 (+1.34%)
     
  • Gold

    1,813.60
    -2.90 (-0.16%)
     
  • Silver

    22.95
    +0.04 (+0.16%)
     
  • EUR/USD

    1.1391
    -0.0019 (-0.17%)
     
  • 10-Yr Bond

    1.7720
    0.0000 (0.00%)
     
  • Vix

    21.54
    +1.23 (+6.06%)
     
  • GBP/USD

    1.3596
    -0.0051 (-0.37%)
     
  • USD/JPY

    114.6050
    +0.0250 (+0.02%)
     
  • BTC-USD

    41,790.37
    -940.93 (-2.20%)
     
  • CMC Crypto 200

    998.93
    -26.80 (-2.61%)
     
  • FTSE 100

    7,569.78
    -41.45 (-0.54%)
     
  • Nikkei 225

    28,257.25
    -76.27 (-0.27%)
     

Mustang Bio Secures $2M NIH Grant For CAR T Cell Therapy Development

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Mustang Bio Inc (NASDAQ: MBIO) has been awarded a grant of approximately million from the National Cancer Institute of the National Institutes of Health (NIH).

  • The two-year award will partially fund the Phase 1 trial to assess the safety, tolerability, and efficacy of MB-106 for relapsed or refractory B-cell non-Hodgkin lymphomas or chronic lymphocytic leukemia.

  • MB-106 is a CD20-targeted, autologous CAR T cell therapy.

  • Related: Mustang Bio's CAR T Cell Therapy Achieves 93% ORR, 67% CR In Mid-Stage Leukemia Trial.

  • In addition, the Office for Human Research Protections has approved Federalwide Assurance for Mustang's research for the protection of human subjects in research.

  • Price Action: MBIO shares are up 3.98% at $2.32 during the market session on the last check Monday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.